Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
DAZAP1 maintains gastric cancer stemness by inducing mitophagy
Peiling Zhang, Wei Wang, Hong Xiang, Yun Zhou, Qian Peng, Guolong Liu, Zhi-Xiang Xu, Lin Lu
Peiling Zhang, Wei Wang, Hong Xiang, Yun Zhou, Qian Peng, Guolong Liu, Zhi-Xiang Xu, Lin Lu
View: Text | PDF
Research Article Cell biology Oncology Stem cells

DAZAP1 maintains gastric cancer stemness by inducing mitophagy

  • Text
  • PDF
Abstract

Stem cells play a pivotal role in the malignant behavior of gastric cancer (GC), complicating its treatment and prognosis. However, the regulatory mechanisms of GC stem cells (GCSCs) remain poorly understood. DAZ-associated protein 1 (DAZAP1), a splicing regulator linked to various malignancies, has an unclear role in GC. This study investigated DAZAP1’s impact on GC stemness and its mechanisms. DAZAP1 promoted tumor progression in GCSCs, as shown by sphere formation assays and stemness marker analysis. Functional enrichment analysis suggested that DAZAP1 enhanced tumor stemness by promoting oxidative phosphorylation (OXPHOS), which was validated through Seahorse assays and measurements of mitochondrial potential. Transmission electron microscopy and immunofluorescence analyses demonstrated that DAZAP1 promoted mitophagy. RNA immunoprecipitation and PCR analysis revealed that DAZAP1 regulated the splicing and expression of the mitophagy-related gene ULK1 through nonsense-mediated mRNA decay. Rescue experiments showed that overexpression of ULK1 reversed the suppression of GC stemness and OXPHOS levels induced by DAZAP1 silencing. Our findings indicate that DAZAP1 reduces ULK1 decay, thereby activating mitophagy and enhancing OXPHOS to fulfill the metabolic demands of cancer stem cells. These findings highlight the therapeutic potential of DAZAP1 as a target for treating GC.

Authors

Peiling Zhang, Wei Wang, Hong Xiang, Yun Zhou, Qian Peng, Guolong Liu, Zhi-Xiang Xu, Lin Lu

×

Figure 4

DAZAP1 promotes stemness properties in GC.

Options: View larger image (or click on image) Download as PowerPoint
DAZAP1 promotes stemness properties in GC.
(A and B) Sphere formation as...
(A and B) Sphere formation assays indicated that DAZAP1 knockdown reduced the number of spheres formed, while overexpression increased sphere-forming ability. (C) Extreme limiting dilution assay (ELDA) indicated that DAZAP1 knockdown decreases self-renewal capacity, while DAZAP1 overexpression enhances it. (D and E) ALDEFLUOR assays showed a decrease in ALDH-high cells with DAZAP1 knockdown and an increase with DAZAP1 overexpression. (F and G) Quantitative PCR (qPCR) and Western blot analyses revealed that DAZAP1 overexpression upregulated stemness markers SOX2, OCT4, and NANOG, while knockdown downregulated these markers. (H and I) In vivo ELDA using DAZAP1-knockdown NCI-N87 cells demonstrated a substantially reduced tumorigenic capacity, requiring higher cell numbers to form detectable tumors compared with control cells. All quantitative data are presented as the mean ± SD of at least 3 independent experiments. Statistical analysis was by unpaired Student’s t test for comparisons between 2 groups and 1-way ANOVA followed by Tukey’s HSD post hoc test for comparisons among 3 groups (B, E, and F). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts